George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
It’s very rare (unprecedented as far as I’m aware) that a company can be so specific in the recruitment of patients in a phase 1 study. There are massive forces in play behind the decisions that have been made (FDA/BP) and the two weekly has the feel of a phase 2/3 efficacy study.
I would be amazed if big pharma hasn’t bought AVCT by this time next year. We shall see
I’m pretty sure that lots of the large sells will be pre sold conversion shares. I make it nearly 5 million round number sells (25k, 50k, 100k, 250k) over the last two weeks.
Once the churn finishes this will re-rate spectacularly imo
Paradigm shift, next frontier, holy grail - these are all words being used to describe what AVACTA has!!
Anyway, I’m looking forward to Al’s presentation where I hope he concentrates on the commercial significance rather than just re-hashing it he science! GLA
Dr Banerji would know ;)
https://x.com/udai_banerji/status/1777778199289581619?s=46&t=kxIabKFV9rIshirb_ZbxHw
As the days and inevitability rolls on I’m sat here wondering at what point institutions start piling into AVCT. It will be at that point when the share price starts to reflect something close to what it’s worth. Seems to me that some specialist funds have to sit up and take little Avacta seriously now!
I mean Dox is dox and AVA6000 releases dox into the tumour so from now on in of course all efficacy results are going to sensational! Unbelievable how the market is sleeping on this one- seems like the biggest open goal investing in AVCT at a market cap anywhere below a billion! Very rarely do you get a pharma with such low risk! GLA
I’m not sure the new shares will be overly churned. I suspect a lot of the private investors that took part in the placing are long term investors that want to bring their average down- or would have sold in the high 50’s their current shares before picking up a new batch at 50p. The CLR is more of a concern however in the short term.
With all the recent horrendous news about Catherine and the media discussion about chemo, wouldn’t now be a great time for AVCT to start talking to the media about what it has achieved to date? Three week dose escalation complete (many patients still receiving treatment) no toxicity- I’m hoping Al seizes the moment after the data is presented in a couple of weeks!